Publications

2021

Elicin O, Vollnberg B, Shelan M, Riggenbach E, Bojaxhiu B, Mathier E, Giger R, Aebersold DM, Klaeser B. Impact of pretreatment second look 18FDG-PET/CT on stage and treatment changes in head and neck cancer. Clin Transl Radiat Oncol. 2021 Aug 29;31:8-13. doi: 10.1016/j.ctro.2021.08.007. PMID: 34504959; PMCID: PMC8414040.

Shelan M, Aebersold DM, Albrecht C, Böhmer D, Flentje M, Ganswindt U, Höcht S, Hölscher T, Müller AC, Niehoff P, Pinkawa M, Schmidt-Hegemann NS, Sedlmayer F, Wolf F, Zamboglou C, Zips D, Wiegel T, Ghadjar P. Moderately hypofractionated radiotherapy as definitive treatment for localized prostate cancer: Pattern of practice in German-speaking countries : A survey of the Prostate Cancer Expert Panel of the German Society of Radiation Oncology (DEGRO) and the Working Party on Radiation Oncology of the German Cancer Society (DKG-ARO). Strahlenther Onkol. 2021 Aug 31. doi: 10.1007/s00066-021-01820-2. Epub ahead of print. PMID: 34463814.

Poel R, Rüfenacht E, Hermann E, Scheib S, Manser P, Aebersold DM, Reyes M. The predictive value of segmentation metrics on dosimetry in organs at risk of the brain. Med Image Anal. 2021 Jul 13;73:102161. doi: 10.1016/j.media.2021.102161. Epub ahead of print. PMID: 34293536.

Ghadjar P, Hayoz S, Bernhard J, Zwahlen DR, Hölscher T, Gut P, Polat B, Hildebrandt G, Müller AC, Plasswilm L, Papachristofilou A, Schär C, Sumila M, Zaugg K, Guckenberger M, Ost P, Reuter C, Bosetti DG, Khanfir K, Gomez S, Wust P, Thalmann GN, Aebersold DM; Swiss Group for Clinical Cancer Research (SAKK). Dose-intensified Versus Conventional-dose Salvage Radiotherapy for Biochemically Recurrent Prostate Cancer After Prostatectomy: The SAKK 09/10 Randomized Phase 3 Trial. Eur Urol. 2021 Sep;80(3):306-315. doi: 10.1016/j.eururo.2021.05.033. Epub 2021 Jun 14. PMID: 34140144.

Ermiş E, Egger R, Leiser D, Anschuetz L, Raabe A, Abu-Isa J, Manser P, Aebersold DM, Wagner F, Herrmann E. Assessment of Tumor Volume Dynamics and Outcome After Radiosurgery for the Treatment of Vestibular Schwannoma: A Single-Center Experience. Otol Neurotol. 2021 Jul 1;42(6):e750-e757. doi: 10.1097/MAO.0000000000003056. PMID: 34111052.

Pinkawa M, Aebersold DM, Böhmer D, Flentje M, Ghadjar P, Schmidt-Hegemann NS, Höcht S, Hölscher T, Müller AC, Niehoff P, Sedlmayer F, Wolf F, Zamboglou C, Zips D, Wiegel T. Radiotherapy in nodal oligorecurrent prostate cancer. Strahlenther Onkol. 2021 Jul;197(7):575-580. doi: 10.1007/s00066-021-01778-1. Epub 2021 Apr 29. PMID: 33914101; PMCID: PMC8219546.

Eychmüller S, Zwahlen S, Fliedner MC, Jüni P, Aebersold DM, Aujesky D, Fey MF, Maessen M, Trelle S. Single early palliative care intervention added to usual oncology care for patients with advanced cancer: A randomized controlled trial (SENS Trial). Palliat Med. 2021 Jun;35(6):1108-1117. doi: 10.1177/02692163211005340. Epub 2021 Apr 28. PMID: 33908288.

Elicin O, Koller Brolese E, Bojaxhiu B, Sermaxhaj B, Schanne DH, Mathier E, Lippmann J, Shelan M, Eller Y, Aebersold DM, Giger R, Cihoric N. The prognostic impact of daytime and seasonality of radiotherapy on head and neck cancer. Radiother Oncol. 2021 May;158:293-299. doi: 10.1016/j.radonc.2021.04.004. Epub 2021 Apr 20. PMID: 33848563.

Melin N, Sánchez-Taltavull D, Fahrner R, Keogh A, Dosch M, Büchi I, Zimmer Y, Medová M, Beldi G, Aebersold DM, Candinas D, Stroka D. Synergistic effect of the TLR5 agonist CBLB502 and its downstream effector IL-22 against liver injury. Cell Death Dis. 2021 Apr 6;12(4):366. doi: 10.1038/s41419-021-03654-3. PMID: 33824326; PMCID: PMC8024273.

Ermiş E, Anschuetz L, Leiser D, Poel R, Raabe A, Manser P, Aebersold DM, Caversaccio M, Mantokoudis G, Abu-Isa J, Wagner F, Herrmann E. Vestibular dose correlates with dizziness after radiosurgery for the treatment of vestibular schwannoma. Radiat Oncol. 2021 Mar 26;16(1):61. doi: 10.1186/s13014-021-01793-7. PMID: 33771181; PMCID: PMC7995572.

Brolese EK, Cihoric N, Bojaxhiu B, Sermaxhaj B, Schanne DH, Mathier E, Lippmann J, Shelan M, Eller Y, Aebersold DM, Giger R, Elicin O. The impact of delivery daytime and seasonality of radiotherapy for head and neck cancer on toxicity burden. Radiother Oncol. 2021 May;158:162-166. doi: 10.1016/j.radonc.2021.02.039. Epub 2021 Mar 3. PMID: 33667582.

Rigendinger F, Aebersold DM, Cvejic Z, Pajic B. Changes of Corneal Biomechanical Properties upon Exclusive Ytt-/Sr-90 Irradiation of Pterygium. Sensors (Basel). 2021 Feb 2;21(3):975. doi: 10.3390/s21030975. PMID: 33540506; PMCID: PMC7867194.

Kueng R, Mueller S, Loebner HA, Frei D, Volken W, Aebersold DM, Stampanoni MFM, Fix MK, Manser P. TriB-RT: Simultaneous optimization of photon, electron and proton beams. Phys Med Biol. 2021 Feb 5;66(4):045006. doi: 10.1088/1361-6560/ab936f. PMID: 32413883.

2020

Bojaxhiu B, Shrestha BK, Luterbacher P, Elicin O, Shelan M, Macpherson AJS, Heimgartner B, Giger R, Aebersold DM, Zaugg K. Unplanned hospitalizations in patients with locoregionally advanced head and neck cancer treated with (chemo)radiotherapy with and without prophylactic percutaneous endoscopic gastrostomy. Radiat Oncol. 2020 Dec 14;15(1):281. doi: 10.1186/s13014-020-01727-9. PMID: 33317602; PMCID: PMC7737384.

Medová M, Medo M, Hovhannisyan L, Muñoz-Maldonado C, Aebersold DM, Zimmer Y. DNA-PK in human malignant disorders: Mechanisms and implications for pharmacological interventions. Pharmacol Ther. 2020 Nov;215:107617. doi: 10.1016/j.pharmthera.2020.107617. Epub 2020 Jun 28. PMID: 32610116.

Achard V, Aebersold DM, Allal AS, Andratschke N, Baumert BG, Beer KT, Betz M, Breuneval T, Bodis S, de Bari B, Förster R, Franzetti-Pellanda A, Guckenberger M, Herrmann E, Huck C, Khanfir K, Matzinger O, Peguret N, Pesce G, Putora PM, Reuter C, Richetti A, Vees H, Vrieling C, Zaugg K, Zimmermann F, Zwahlen DR, Tsoutsou P, Zilli T. A national survey on radiation oncology patterns of practice in Switzerland during the COVID-19 pandemic: Present changes and future perspectives. Radiother Oncol. 2020 Sep;150:1-3. doi: 10.1016/j.radonc.2020.05.047. Epub 2020 Jun 6. PMID: 32512075; PMCID: PMC7274968.

Ermiş E, Jungo A, Poel R, Blatti-Moreno M, Meier R, Knecht U, Aebersold DM, Fix MK, Manser P, Reyes M, Herrmann E. Fully automated brain resection cavity delineation for radiation target volume definition in glioblastoma patients using deep learning. Radiat Oncol. 2020 May 6;15(1):100. doi: 10.1186/s13014-020-01553-z. PMID: 32375839; PMCID: PMC7204033.

Bensimon A, Koch JP, Francica P, Roth SM, Riedo R, Glück AA, Orlando E, Blaukat A, Aebersold DM, Zimmer Y, Aebersold R, Medová M. Deciphering MET-dependent modulation of global cellular responses to DNA damage by quantitative phosphoproteomics. Mol Oncol. 2020 Jun;14(6):1185-1206. doi: 10.1002/1878-0261.12696. Epub 2020 May 13. PMID: 32336009; PMCID: PMC7266272.

Ghadjar P, Aebersold DM, Albrecht C, Böhmer D, Flentje M, Ganswindt U, Höcht S, Hölscher T, Müller AC, Niehoff P, Pinkawa M, Sedlmayer F, Zips D, Wiegel T; Prostate Cancer Expert Panel of the German Society of Radiation Oncology (DEGRO) and The Working Party Radiation Oncology of the German Cancer Society (DKG-ARO). Treatment strategies to prevent and reduce gynecomastia and/or breast pain caused by antiandrogen therapy for prostate cancer : Statement from the DEGRO working group prostate cancer. Strahlenther Onkol. 2020 Jul;196(7):589-597. doi: 10.1007/s00066-020-01598-9. Epub 2020 Mar 12. PMID: 32166452; PMCID: PMC7305090.

Vees H, Caparrotti F, Eboulet EI, Xyrafas A, Fuhrer A, Meier U, Mark M, Elicin O, Aebersold DM, Zwahlen DR, Finazzi T, Allal AS, Putora PM, Martucci F, Rudolf CB, Ribi K; Swiss Group for Clinical Cancer Research (SAKK). Impact of Early Prophylactic Cranial Irradiation With Hippocampal Avoidance on Neurocognitive Function in Patients With Limited Disease Small Cell Lung Cancer. A Multicenter Phase 2 Trial (SAKK 15/12). Int J Radiat Oncol Biol Phys. 2020 Jun 1;107(2):279-287. doi: 10.1016/j.ijrobp.2020.02.029. Epub 2020 Mar 4. PMID: 32142869.

Panje CM, Lupatsch JE, Barbier M, Pardo E, Lorez M, Dedes KJ, Aebersold DM, Plasswilm L, Gautschi O, Schwenkglenks M; Swiss Group for Clinical Cancer Research (SAKK). A cost-effectiveness analysis of consolidation immunotherapy with durvalumab in stage III NSCLC responding to definitive radiochemotherapy in Switzerland. Ann Oncol. 2020 Apr;31(4):501-506. doi: 10.1016/j.annonc.2020.01.007. Epub 2020 Jan 16. PMID: 32107097.

Koch JP, Aebersold DM, Zimmer Y, Medová M. MET targeting: time for a rematch. Oncogene. 2020 Apr;39(14):2845-2862. doi: 10.1038/s41388-020-1193-8. Epub 2020 Feb 7. PMID: 32034310.

Beck M, Böhmer D, Aebersold DM, Albrecht C, Flentje M, Ganswindt U, Höcht S, Hölscher T, Müller AC, Niehoff P, Pinkawa M, Sedlmayer F, Zips D, Zschaeck S, Budach V, Wiegel T, Ghadjar P; Prostate Cancer Expert Panel of the German Society of Radiation Oncology (DEGRO) and the Working Party Radiation Oncology of the German Cancer Society (DKG-ARO). Role of combined radiation and androgen deprivation therapy in intermediate-risk prostate cancer : Statement from the DEGRO working group on prostate cancer. Strahlenther Onkol. 2020 Feb;196(2):109-116. doi: 10.1007/s00066-019-01553-3. Epub 2019 Nov 29. PMID: 31784804.

Nisa L, Francica P, Giger R, Medo M, Elicin O, Friese-Hamim M, Wilm C, Stroh C, Bojaxhiu B, Quintin A, Caversaccio MD, Dettmer MS, Buchwalder M, Brodie TM, Aebersold DM, Zimmer Y, Carey TE, Medová M. Targeting the MET Receptor Tyrosine Kinase as a Strategy for Radiosensitization in Locoregionally Advanced Head and Neck Squamous Cell Carcinoma. Mol Cancer Ther. 2020 Feb;19(2):614-626. doi: 10.1158/1535-7163.MCT-18-1274. Epub 2019 Nov 19. PMID: 31744898.

Medo M.: Contact network models matching the dynamics of the covid-19 spreading. Journal of Physics A: Mathematical and Theoretical 54 (3), 035601, 2020.

2019

Medo M, Aebersold DM, Medová M. ProtRank: bypassing the imputation of missing values in differential expression analysis of proteomic data. BMC Bioinformatics. 2019 Nov 9;20(1):563. doi: 10.1186/s12859-019-3144-3. PMID: 31706265; PMCID: PMC6842221.

Elicin O, Ermiş E, Oehler C, Aebersold DM, Caparrotti F, Zimmermann F, Studer G, Henke G, Adam L, Anschuetz L, Ozsahin M, Guckenberger M, Shelan M, Kaydıhan N, Riesterer O, Prestwich RJD, Spielmann T, Giger R, Şen M. Influencing Factors on Radiotherapy Outcome in Stage I-II Glottic Larynx Cancer-A Multicenter Study. Front Oncol. 2019 Sep 20;9:932. doi: 10.3389/fonc.2019.00932. PMID: 31616637; PMCID: PMC6763757.

Mackeprang PH, Vuong D, Volken W, Henzen D, Schmidhalter D, Malthaner M, Mueller S, Frei D, Kilby W, Aebersold DM, Fix MK, Manser P. Benchmarking Monte-Carlo dose calculation for MLC CyberKnife treatments. Radiat Oncol. 2019 Sep 18;14(1):172. doi: 10.1186/s13014-019-1370-5. PMID: 31533746; PMCID: PMC6751815.

Kueng R, Frei D, Volken W, Stuermlin F, M Stampanoni MF, Aebersold DM, Manser P, Fix MK. Adaptive step size algorithm to increase efficiency of proton macro Monte Carlo dose calculation. Radiat Oncol. 2019 Sep 9;14(1):165. doi: 10.1186/s13014-019-1362-5. PMID: 31500647; PMCID: PMC6734301.

Hoyle AP, Ali A, James ND, Cook A, Parker CC, de Bono JS, Attard G, Chowdhury S, Cross WR, Dearnaley DP, Brawley CD, Gilson C, Ingleby F, Gillessen S, Aebersold DM, Jones RJ, Matheson D, Millman R, Mason MD, Ritchie AWS, Russell M, Douis H, Parmar MKB, Sydes MR, Clarke NW; STAMPEDE Investigators. Abiraterone in "High-" and "Low-risk" Metastatic Hormone-sensitive Prostate Cancer. Eur Urol. 2019 Dec;76(6):719-728. doi: 10.1016/j.eururo.2019.08.006. Epub 2019 Aug 23. PMID: 31447077.

Riesterer O, Ciernik IF, Stahel RA, Xyrafas A, Aebersold DM, Plasswilm L, Mahmut Ozsahin E, Zwahlen DR, Nackaerts K, Zimmermann F, Sabrina Stark L, Weder W, Krayenbuehl J; Swiss Group for Clinical Cancer Research (SAKK). Pattern of failure after adjuvant radiotherapy following extrapleural pneumonectomy of pleural mesothelioma in the SAKK 17/04 trial. Radiother Oncol. 2019 Sep;138:121-125. doi: 10.1016/j.radonc.2019.05.024. Epub 2019 Jun 25. PMID: 31252293.

Hemmatazad H, Schmidhalter D, Elicin O, Aebersold DM, Herrmann E. Skin surface markers for stereotactic body radiation therapy of sternal metastasis. Rep Pract Oncol Radiother. 2019 Jul-Aug;24(4):322-324. doi: 10.1016/j.rpor.2019.05.005. Epub 2019 May 30. PMID: 31193944; PMCID: PMC6545360.

Poliaková M, Felser A, Pierzchala K, Nuoffer JM, Aebersold DM, Zimmer Y, Zamboni N, Medová M. Metabolomics reveals tepotinib-related mitochondrial dysfunction in MET-activating mutations-driven models. FEBS J. 2019 Jul;286(14):2692-2710. doi: 10.1111/febs.14852. Epub 2019 May 11. PMID: 30993872.

Shelan M, Odermatt S, Bojaxhiu B, Nguyen DP, Thalmann GN, Aebersold DM, Dal Pra A. Disease Control With Delayed Salvage Radiotherapy for Macroscopic Local Recurrence Following Radical Prostatectomy. Front Oncol. 2019 Feb 28;9:12. doi: 10.3389/fonc.2019.00012. PMID: 30873377; PMCID: PMC6403145.

Bachmann N, Leiser D, Ermis E, Vulcu S, Schucht P, Raabe A, Aebersold DM, Herrmann E. Impact of regular magnetic resonance imaging follow-up after stereotactic radiotherapy to the surgical cavity in patients with one to three brain metastases. Radiat Oncol. 2019 Mar 14;14(1):45. doi: 10.1186/s13014-019-1252-x. PMID: 30871597; PMCID: PMC6417038.

Correia D, Terribilini D, Zepter S, Pica A, Bizzocchi N, Volken W, Stieb S, Ahlhelm F, Herrmann E, Fix MK, Manser P, Aebersold DM, Weber DC. Whole-ventricular irradiation for intracranial germ cell tumors: Dosimetric comparison of pencil beam scanned protons, intensity-modulated radiotherapy and volumetric-modulated arc therapy. Clin Transl Radiat Oncol. 2019 Jan 9;15:53-61. doi: 10.1016/j.ctro.2019.01.002. PMID: 30734001; PMCID: PMC6357692.

Elicin O, Broglie MA, Fankhauser N, Stoeckli SJ, Pasche P, Reinhard A, Bongiovanni M, Huber GF, Morand GB, Soltermann A, Arnold A, Dettmer MS, Arnoux A, Stauffer E, Espeli V, Martucci F, Aebersold DM, Giger R. Comparison of contemporary staging systems for oropharynx cancer in a surgically treated multi-institutional cohort. Head Neck. 2019 May;41(5):1395-1402. doi: 10.1002/hed.25574. Epub 2018 Dec 28. PMID: 30593685.

Orlando E, Aebersold DM, Medová M, Zimmer Y. Oncogene addiction as a foundation of targeted cancer therapy: The paradigm of the MET receptor tyrosine kinase. Cancer Lett. 2019 Feb 28;443:189-202. doi: 10.1016/j.canlet.2018.12.001. Epub 2018 Dec 11. PMID: 30550851.

Elicin O, Sermaxhaj B, Bojaxhiu B, Shelan M, Giger R, Rauch D, Aebersold DM. Incidence of second primary cancers after radiotherapy combined with platinum and/or cetuximab in head and neck cancer patients. Strahlenther Onkol. 2019 Jun;195(6):468-474. English. doi: 10.1007/s00066-018-1400-5. Epub 2018 Nov 21. PMID: 30465265.